Breakthrough Data on Pediatric Use of Pretomanid for Drug-Resistant Tuberculosis Unveiled at 2025 Union Conference New interim findings from the IMPAACT 2034 study highlight valuable insights into the safety and efficacy of pretomanid for treating drug-resistant tuberculosis in children.

Breakthrough Data on Pediatric Use of Pretomanid for Drug-Resistant Tuberculosis Unveiled at 2025 Union Conference #Denmark #Copenhagen #pretomanid #RR-TB #IMPAACT